Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada
has issued a Notice of Compliance for Harvoni™ (ledipasvir 90
mg/sofosbuvir 400 mg), the first once-daily single table regimen for the
treatment of chronic hepatitis C genotype 1 infection in adults.
for Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C investment picks